Although cancer is not usually inherited, certain types, including breast and ovarian, can be triggered by inherited gene faults, meaning they can run in families. Now that we can test for these ...

Scientists have discovered a key protein that could be targeted with a drug to treat the most common and aggressive form of pancreatic cancer. The findings, published in Nature, show that blocking the ...

Over the last four decades, radiotherapy has seen a technological revolution – evolving from broad, relatively simple deliveries to highly targeted, patient-specific treatment. Few individuals have ...

A one-time immunotherapy treatment using a patient’s own immune cells has shown long-lasting benefit for people with advanced melanoma, a serious form of skin cancer, according to new five-year follow ...

A new AI test can pick out which men with high-risk prostate cancer that has not spread will require life-extending drug abiraterone. Scientists from The Institute of Cancer Research, London, and ...

As we enter 2026, scientists at The Institute of Cancer Research, London, share the developments expected this year that could soon change how cancer is treated – from technologies designed to deliver ...

A new type of cancer treatment which is given via an injection under the skin has shown early signs of success in patients with advanced head and neck cancer. Results of the phase Ib/II Orig-AMI 4 ...

Scientists have created the most comprehensive map to date of the genetic mutations that fuel cancer – opening the door to extending precision treatments to thousands more patients and offering clues ...

Up to two in five advanced prostate cancer patients could be treated with a combination of two targeted drugs, according to new research. Findings by a team of scientists at The Institute of Cancer ...

Cancer cases in both younger and older adults are increasing, challenging the idea that a global rise is only occurring in the under 50s, a major new analysis has found. An international study, led by ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend the targeted breast cancer drug, capivasertib, in combination with fulvestrant, for treating the most ...

The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have announced a new licensing agreement with MedTech company Mint Medical, a Snke Company, to improve monitoring ...